335 related articles for article (PubMed ID: 28544785)
1. Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma.
Xue LJ; Mao XB; Ren LL; Chu XY
Cancer Med; 2017 Jun; 6(6):1424-1436. PubMed ID: 28544785
[TBL] [Abstract][Full Text] [Related]
2. CXCL12-CXCR4/CXCR7 Axis in Colorectal Cancer: Therapeutic Target in Preclinical and Clinical Studies.
Khare T; Bissonnette M; Khare S
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298991
[TBL] [Abstract][Full Text] [Related]
3. Therapeutics target of CXCR4 and its downstream in peritoneal carcinomatosis of gastric cancer.
Koizumi K; Kato S; Sakurai H; Hashimoto I; Yasumoto K; Saiki I
Front Biosci (Schol Ed); 2012 Jan; 4(1):269-76. PubMed ID: 22202059
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
Qiao N; Wang L; Wang T; Li H
Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive imaging reveals inhibition of ovarian cancer by targeting CXCL12-CXCR4.
Ray P; Lewin SA; Mihalko LA; Schmidt BT; Luker KE; Luker GD
Neoplasia; 2011 Dec; 13(12):1152-61. PubMed ID: 22241961
[TBL] [Abstract][Full Text] [Related]
6. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
Zhou Y; Cao HB; Li WJ; Zhao L
Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
[TBL] [Abstract][Full Text] [Related]
7. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
Nazari A; Khorramdelazad H; Hassanshahi G
Int J Clin Oncol; 2017 Dec; 22(6):991-1000. PubMed ID: 29022185
[TBL] [Abstract][Full Text] [Related]
8. The role of the CXCR4/CXCL12 axis and its clinical implications in gastric cancer.
Lee HJ; Jo DY
Histol Histopathol; 2012 Sep; 27(9):1155-61. PubMed ID: 22806902
[TBL] [Abstract][Full Text] [Related]
9. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
Zhou W; Guo S; Liu M; Burow ME; Wang G
Curr Med Chem; 2019; 26(17):3026-3041. PubMed ID: 28875842
[TBL] [Abstract][Full Text] [Related]
10. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
[TBL] [Abstract][Full Text] [Related]
11. LncRNA COL1A1-014 is involved in the progression of gastric cancer via regulating CXCL12-CXCR4 axis.
Dong XZ; Zhao ZR; Hu Y; Lu YP; Liu P; Zhang L
Gastric Cancer; 2020 Mar; 23(2):260-272. PubMed ID: 31650323
[TBL] [Abstract][Full Text] [Related]
12. HMGA1B/2 transcriptionally activated-POU1F1 facilitates gastric carcinoma metastasis via CXCL12/CXCR4 axis-mediated macrophage polarization.
Tang C; Lei X; Xiong L; Hu Z; Tang B
Cell Death Dis; 2021 Apr; 12(5):422. PubMed ID: 33927188
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
Scala S
Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells.
Chen G; Chen SM; Wang X; Ding XF; Ding J; Meng LH
J Biol Chem; 2012 Apr; 287(15):12132-41. PubMed ID: 22337890
[TBL] [Abstract][Full Text] [Related]
15. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
[TBL] [Abstract][Full Text] [Related]
16. CXCR7 is not obligatory for CXCL12-CXCR4-induced epithelial-mesenchymal transition in human ovarian cancer.
Zheng N; Liu W; Chen J; Li B; Liu J; Wang J; Gao Y; Shao J; Jia L
Mol Carcinog; 2019 Jan; 58(1):144-155. PubMed ID: 30259564
[TBL] [Abstract][Full Text] [Related]
17. Relevance of the CXCR4/CXCR7-CXCL12 axis and its effect in pathophysiological conditions.
Huynh C; Dingemanse J; Meyer Zu Schwabedissen HE; Sidharta PN
Pharmacol Res; 2020 Nov; 161():105092. PubMed ID: 32758634
[TBL] [Abstract][Full Text] [Related]
18. Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway.
Xu D; Li R; Wu J; Jiang L; Zhong HA
Curr Top Med Chem; 2016; 16(13):1441-51. PubMed ID: 26369824
[TBL] [Abstract][Full Text] [Related]
19. CXCR4/SDF-1 axis is involved in lymph node metastasis of gastric carcinoma.
Zhao BC; Wang ZJ; Mao WZ; Ma HC; Han JG; Zhao B; Xu HM
World J Gastroenterol; 2011 May; 17(19):2389-96. PubMed ID: 21633638
[TBL] [Abstract][Full Text] [Related]
20. CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells.
Ieranò C; Santagata S; Napolitano M; Guardia F; Grimaldi A; Antignani E; Botti G; Consales C; Riccio A; Nanayakkara M; Barone MV; Caraglia M; Scala S
Cell Death Dis; 2014 Jul; 5(7):e1310. PubMed ID: 24991762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
